Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells

Table 1 Celecoxib inhibited prostaglandin E₂ secretion by breast cancer cells

Treatment	MDA-MB-231	P value	MDA-MB-468	P value
Vehicle	430.0 ± 178.2		76.6 ± 15.2
Celecoxib 20 μmol/l	30.1 ± 2.9	<0.01	39.0 ± 16.5	0.03
Celecoxib 40 μmol/l	30.7 ± 4.7	<0.01	37.3 ± 11.0	0.02
Celecoxib 60 μmol/l	37.7 ± 13.6	<0.01	30.3 ± 13.6	0.01

Forty-eight hours post treatment, conditioned medium from vehicle and celecoxib (20–60 μmol/l) treated cells were harvested and prostaglandin (PG)E₂ levels (pg/ml) determined by enzyme-linked immunosorbent assay. In all cell lines, PGE₂ levels were significantly reduced at all doses of celecoxib. The experiment was repeated three times and in triplicate. P values represent significant differences between vehicle control and celecoxib treatment.

ISSN: 1465-542X